Back to Results
First PageMeta Content
Pharmaceutical companies


Avaxia Biologics Elects Christopher Kiritsy to its Board of Directors LEXINGTON, Mass. – April 26, 2012 – Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop
Add to Reading List

Document Date: 2014-02-06 00:38:27

Open Document

File Size: 88,87 KB

Share Result on Facebook

Company

Avaxia Biologics Inc. / Arisaph Pharmaceuticals Inc. / Abbott Laboratories / Kos Pharmaceuticals Inc. / /

Country

United States / /

Currency

USD / /

Event

Employment Change / FDA Phase / IPO / M&A / Funding / /

Facility

Bowdoin College / Boston University / Institute of Molecular Biology / /

IndustryTerm

manufacturing clinical materials / platform technology / therapeutics for the treatment of gastrointestinal diseases / finance / pharmaceutical / /

MedicalCondition

IBD / inflammatory bowel disease / gastrointestinal diseases / /

Organization

Board of Directors LEXINGTON / Institute of Molecular Biology / Bowdoin College / U.S. government / Boston University / Board of Avaxia / /

Person

Barbara Fox / Christopher Kiritsy / /

Position

Director of Product Development / co-founder and President and Chief Executive Officer / Director / CEO and a member of the Board / President and Chief Executive Officer / Executive Vice President / Corporate Development and Chief Financial Officer / entrepreneur / seasoned entrepreneur / member of the board / /

Product

Niaspan / IBD / /

ProvinceOrState

A.B. / Massachusetts / /

PublishedMedium

Fortune Magazine / Molecular Biology / /

Technology

platform technology / /

SocialTag